Trial Details
COMPLETEDBasic Information
| Clinical ID | c1454 |
|---|---|
| Identifier | NCT05013905 |
| Trial Title | A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Crohn Disease |
| Interventions | DRUG: PRA023 IV|DEVICE: Companion diagnostic (CDx) |
Participant Information
| Sponsor | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
|---|---|
| City | Los Angeles |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2021-07-28 |
|---|---|
| Primary Completion Date | 2022-09-23 |
| Completion Date | 2025-05-27 |